MAbs were developed against specific cell surface antigens on the majority of diseased cells from B-ALL patients (CD19, CD20, CD22 and CD52) and exert their function through antibody-dependent cytotoxicity, complement-dependent cytotoxicity and direct induction of apoptosis [5, 7]. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.